Satralizumab wins FDA approval for NMOSD
- Posted on: Aug 18 2020
- Leave a response
The FDA has approved satralizumab (Enspryng) for neuromyelitis optica spectrum disorder (NMOSD), making Genentech’s drug the first and only injectable treatment for the rare disease.
Source: AAO
Posted in: Uncategorized
